Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Halozyme Therapeutics: Q4 Earnings Snapshot AP - Tue Feb 20, 3:15PM CST

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 39.12 (+0.38%)
Plexus, SunPower fall; Progress Software, Masonite International rise, Wednesday, 1/17/2024 Associated Press - Wed Jan 17, 3:13PM CST

Stocks that traded heavily or had substantial price changes on Wednesday: Plexus, SunPower fall; Progress Software, Masonite International rise

PLXS : 95.67 (-0.94%)
SPWR : 1.9400 (-1.02%)
BGFV : 3.33 (unch)
PRGS : 51.63 (+0.39%)
HALO : 39.12 (+0.38%)
PI : 120.91 (-2.24%)
DOOR : 131.60 (+0.24%)
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond Motley Fool - Tue Jan 16, 9:30AM CST

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

CNC : 76.19 (+0.46%)
HALO : 39.12 (+0.38%)
ABCL : 3.90 (-1.76%)
HUM : 315.98 (-3.66%)
Halozyme Therapeutics: Q3 Earnings Snapshot AP - Mon Nov 6, 2023

Halozyme Therapeutics: Q3 Earnings Snapshot

HALO : 39.12 (+0.38%)
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from...

HALO : 39.12 (+0.38%)
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference PR Newswire - Mon Oct 16, 2023

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") will present the positive results of a clinical study demonstrating subcutaneous...

HALO : 39.12 (+0.38%)
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's...

HALO : 39.12 (+0.38%)
Healthcare - iStock-1346675584
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar OTOS Inc. - Fri Aug 25, 2023

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 39.12 (+0.38%)
KNSA : 17.86 (+1.02%)
ACAD : 16.59 (-0.90%)
HRMY : 29.23 (+1.32%)
AMPH : 41.00 (+0.22%)
INCY : 51.74 (+0.17%)
AGEN : 7.42 (+14.86%)
NVS : 98.35 (+1.10%)
PFE : 26.27 (-0.19%)
SGEN : 228.74 (-0.07%)
MRK : 127.00 (+0.09%)
RXDX : 199.92 (+0.09%)
Halozyme Therapeutics: Q2 Earnings Snapshot AP - Tue Aug 8, 2023

Halozyme Therapeutics: Q2 Earnings Snapshot

HALO : 39.12 (+0.38%)
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire - Tue Aug 8, 2023

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second...

HALO : 39.12 (+0.38%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip Barchart - Wed Apr 24, 6:30PM CDT
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot